Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Amir T Fathi

Showing results (21-30 of 180) with videos related to

Pageof 18
Sort By:
American Journal of Hematology|May 9, 2012
Pure erythroid leukemia evolving from a therapy-related myelodysplastic syndrome secondary to treatment for chronic lymphocytic leukemiaHossein Sadrzadeh, Robert Hasserjian, Amir T Fathi
Discovery Medicine|January 1, 2013
Infectious pathogens and hematologic malignancyHossein Sadrzadeh, Seyed M Abtahi, Amir T Fathi
Cancer Treatment Reviews|January 9, 2010
Exploiting cellular pathways to develop new treatment strategies for AMLAmir T Fathi, Steven Grant, Judith E Karp
Discovery Medicine|December 30, 2011
Molecular alterations underlying eosinophilic and mast cell malignanciesHossein Sadrzadeh, Omar Abdel-Wahab, Amir T Fathi
Therapeutic Advances in Hematology|June 3, 2014
The evolving role of FLT3 inhibitors in acute myeloid leukemia: quizartinib and beyondSeth A Wander, Mark J Levis, Amir T Fathi
Oncotargets and Therapy|June 22, 2018
Reformulating acute myeloid leukemia: liposomal cytarabine and daunorubicin (CPX-351) as an emerging therapy for secondary AMLEvan C Chen, Amir T Fathi, Andrew M Brunner
Protein & Cell|August 29, 2013
The evolving landscape in the therapy of acute myeloid leukemiaGrace L Peloquin, Yi-Bin Chen, Amir T Fathi
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|May 27, 2014
New molecular abnormalities and clonal architecture in AML: from reciprocal translocations to whole-genome sequencingTimothy A Graubert, Andrew M Brunner, Amir T Fathi
Pharmacology & Therapeutics|March 19, 2017
Isocitrate dehydrogenase (IDH) inhibition as treatment of myeloid malignancies: Progress and future directionsVivek A Upadhyay, Andrew M Brunner, Amir T Fathi
Leukemia & Lymphoma|September 15, 2023
Temporal trend in survival for chronic myelomonocytic leukemia in the US: a population-based studyArnaud Lesegretain, Andrew Brunner, Aziz Benzohra, et al.
Pageof 18

Showing results (21-30 of 180) with videos related to

Sort By:
Pageof 18
American Journal of Hematology|May 9, 2012
Pure erythroid leukemia evolving from a therapy-related myelodysplastic syndrome secondary to treatment for chronic lymphocytic leukemiaHossein Sadrzadeh, Robert Hasserjian, Amir T Fathi
Discovery Medicine|January 1, 2013
Infectious pathogens and hematologic malignancyHossein Sadrzadeh, Seyed M Abtahi, Amir T Fathi
Cancer Treatment Reviews|January 9, 2010
Exploiting cellular pathways to develop new treatment strategies for AMLAmir T Fathi, Steven Grant, Judith E Karp
Discovery Medicine|December 30, 2011
Molecular alterations underlying eosinophilic and mast cell malignanciesHossein Sadrzadeh, Omar Abdel-Wahab, Amir T Fathi
Therapeutic Advances in Hematology|June 3, 2014
The evolving role of FLT3 inhibitors in acute myeloid leukemia: quizartinib and beyondSeth A Wander, Mark J Levis, Amir T Fathi
Oncotargets and Therapy|June 22, 2018
Reformulating acute myeloid leukemia: liposomal cytarabine and daunorubicin (CPX-351) as an emerging therapy for secondary AMLEvan C Chen, Amir T Fathi, Andrew M Brunner
Protein & Cell|August 29, 2013
The evolving landscape in the therapy of acute myeloid leukemiaGrace L Peloquin, Yi-Bin Chen, Amir T Fathi
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|May 27, 2014
New molecular abnormalities and clonal architecture in AML: from reciprocal translocations to whole-genome sequencingTimothy A Graubert, Andrew M Brunner, Amir T Fathi
Pharmacology & Therapeutics|March 19, 2017
Isocitrate dehydrogenase (IDH) inhibition as treatment of myeloid malignancies: Progress and future directionsVivek A Upadhyay, Andrew M Brunner, Amir T Fathi
Leukemia & Lymphoma|September 15, 2023
Temporal trend in survival for chronic myelomonocytic leukemia in the US: a population-based studyArnaud Lesegretain, Andrew Brunner, Aziz Benzohra, et al.
Pageof 18